CN110869390A - 抗pd-l1抗体及其用途 - Google Patents

抗pd-l1抗体及其用途 Download PDF

Info

Publication number
CN110869390A
CN110869390A CN201880044363.1A CN201880044363A CN110869390A CN 110869390 A CN110869390 A CN 110869390A CN 201880044363 A CN201880044363 A CN 201880044363A CN 110869390 A CN110869390 A CN 110869390A
Authority
CN
China
Prior art keywords
antibody
seq
variant
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880044363.1A
Other languages
English (en)
Other versions
CN110869390B (zh
Inventor
李博华
王华菁
何晓文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oricell Therapeutics Co Ltd
Original Assignee
Shanghai OriginCell Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai OriginCell Medical Technology Co Ltd filed Critical Shanghai OriginCell Medical Technology Co Ltd
Priority to CN202110430146.XA priority Critical patent/CN113087799B/zh
Priority to CN202211353129.1A priority patent/CN115991778A/zh
Priority to CN202110431887.XA priority patent/CN113121698B/zh
Publication of CN110869390A publication Critical patent/CN110869390A/zh
Application granted granted Critical
Publication of CN110869390B publication Critical patent/CN110869390B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

提供与PD‑L1蛋白或CD137蛋白结合的抗体、其抗原结合片段或变体，以及即可与PD‑L1蛋白相结合有可与CD137蛋白结合的双特异性抗体。所述的双特异性抗体对PD‑L1蛋白和CD137蛋白的特异性识别能力强，可以增强T细胞活性。还提供了所述抗体或其抗原结合片段或变体和所述双特异性抗体在预防和***中的应用。

Description

PCT国内申请，说明书已公开。

Claims (72)

  1. PCT国内申请，权利要求书已公开。
CN201880044363.1A 2018-04-09 2018-08-27 抗pd-l1抗体及其用途 Active CN110869390B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202110430146.XA CN113087799B (zh) 2018-04-09 2018-08-27 抗pd-l1抗体及其用途
CN202211353129.1A CN115991778A (zh) 2018-04-09 2018-08-27 抗pd-l1抗体及其用途
CN202110431887.XA CN113121698B (zh) 2018-04-09 2018-08-27 抗pd-l1抗体及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018103093025 2018-04-09
CN201810309302 2018-04-09
PCT/CN2018/102584 WO2019196309A1 (zh) 2018-04-09 2018-08-27 抗pd-l1抗体及其用途

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202110430146.XA Division CN113087799B (zh) 2018-04-09 2018-08-27 抗pd-l1抗体及其用途
CN202211353129.1A Division CN115991778A (zh) 2018-04-09 2018-08-27 抗pd-l1抗体及其用途
CN202110431887.XA Division CN113121698B (zh) 2018-04-09 2018-08-27 抗pd-l1抗体及其用途

Publications (2)

Publication Number Publication Date
CN110869390A true CN110869390A (zh) 2020-03-06
CN110869390B CN110869390B (zh) 2021-05-11

Family

ID=68163043

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202110431887.XA Active CN113121698B (zh) 2018-04-09 2018-08-27 抗pd-l1抗体及其用途
CN201880044363.1A Active CN110869390B (zh) 2018-04-09 2018-08-27 抗pd-l1抗体及其用途
CN202110430146.XA Active CN113087799B (zh) 2018-04-09 2018-08-27 抗pd-l1抗体及其用途
CN202211353129.1A Pending CN115991778A (zh) 2018-04-09 2018-08-27 抗pd-l1抗体及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110431887.XA Active CN113121698B (zh) 2018-04-09 2018-08-27 抗pd-l1抗体及其用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202110430146.XA Active CN113087799B (zh) 2018-04-09 2018-08-27 抗pd-l1抗体及其用途
CN202211353129.1A Pending CN115991778A (zh) 2018-04-09 2018-08-27 抗pd-l1抗体及其用途

Country Status (17)

Country Link
US (1) US11993655B2 (zh)
EP (1) EP3778635A4 (zh)
JP (2) JP7360720B2 (zh)
KR (1) KR20200140882A (zh)
CN (4) CN113121698B (zh)
AU (1) AU2018418224A1 (zh)
BR (1) BR112020020637A2 (zh)
CA (1) CA3095498A1 (zh)
CL (1) CL2020002600A1 (zh)
CO (1) CO2020013833A2 (zh)
EA (1) EA202092420A1 (zh)
IL (2) IL297847B2 (zh)
MX (1) MX2020010653A (zh)
PH (1) PH12020551661A1 (zh)
SG (1) SG11202009791VA (zh)
WO (1) WO2019196309A1 (zh)
ZA (1) ZA202006255B (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023000675A1 (zh) * 2021-07-23 2023-01-26 安徽安科生物工程（集团）股份有限公司 靶向pd-l1和4-1bb的双特异性抗体
CN116120461A (zh) * 2022-04-29 2023-05-16 德琪(杭州)生物有限公司 新型抗药抗体以及其用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023004598A (es) 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
CN116710556A (zh) * 2021-01-08 2023-09-05 北京韩美药品有限公司 抗pd-l1/抗4-1bb天然抗体结构样异源二聚体形式双特异抗体及其制备
WO2023134657A1 (zh) * 2022-01-11 2023-07-20 原启生物科技(上海)有限责任公司 抗cldn18.2和4-1bb的双特异性抗原结合蛋白及其用途
WO2023138638A1 (zh) * 2022-01-24 2023-07-27 原启生物科技(上海)有限责任公司 抗tigit和pd-l1的双特异性抗原结合蛋白及其用途
CN114736303A (zh) * 2022-03-17 2022-07-12 英诺湖医药(杭州)有限公司 抗pd-l1和4-1bb的双功能抗体及其医药用途

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248089A (zh) * 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
CN104994873A (zh) * 2012-10-04 2015-10-21 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
CN105669862A (zh) * 2014-11-21 2016-06-15 上海中信国健药业股份有限公司 抗人pd-l1/kir双特异性抗体及其制备方法和应用
CN105777906A (zh) * 2014-12-19 2016-07-20 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
CN106699891A (zh) * 2017-01-25 2017-05-24 北京天广实生物技术股份有限公司 一种抗pd‑l1 抗体、其药物组合物及其用途
CN106939047A (zh) * 2016-01-04 2017-07-11 钜川生物医药 一种pd-l1抗体及其制备方法
CN107001463A (zh) * 2014-08-05 2017-08-01 中美冠科生物技术（太仓）有限公司 抗pd‑l1抗体
CN107298713A (zh) * 2017-08-15 2017-10-27 联合益康（北京）生物科技有限公司 一种抗pd‑l1抗体及应用、制备方法、试剂盒和药物
CN107428832A (zh) * 2015-01-09 2017-12-01 新加坡科技研究局 抗pd‑l1抗体
CN107488229A (zh) * 2016-06-13 2017-12-19 臧敬五 Pd‑l1抗体及其用途
WO2018057669A1 (en) * 2016-09-21 2018-03-29 Alexo Therapeutics Inc. Antibodies against signal-regulatory protein alpha and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
WO2015119923A1 (en) 2014-02-04 2015-08-13 Pfizer Inc. Combination of a pd-1 antagonist and a 4-abb agonist for treating cancer
CN105017421B (zh) * 2014-04-16 2017-12-26 中国人民解放军海军总医院 一种抗her2双特异性抗体及其制备方法与应用
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
MX2017016324A (es) * 2015-06-16 2018-03-02 Merck Patent Gmbh Tratamientos de combinacion de antagonista de ligando 1 de muerte programada (pd-l1).
SG11201806496SA (en) * 2016-01-29 2018-08-30 Heyue Zhou Antigen binding proteins that bind pd-l1
MY190771A (en) 2016-06-13 2022-05-12 I Mab Biopharma Us Ltd Anti-pd-l1 antibodies and uses thereof
AU2017300788B2 (en) * 2016-07-22 2023-11-16 Dana-Farber Cancer Institute, Inc. Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
CN109983033B (zh) 2016-09-23 2023-10-31 美勒斯公司 调节细胞表达的生物活性的结合分子

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248089A (zh) * 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
CN105330741A (zh) * 2005-07-01 2016-02-17 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
CN104994873A (zh) * 2012-10-04 2015-10-21 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
CN107001463A (zh) * 2014-08-05 2017-08-01 中美冠科生物技术（太仓）有限公司 抗pd‑l1抗体
CN105669862A (zh) * 2014-11-21 2016-06-15 上海中信国健药业股份有限公司 抗人pd-l1/kir双特异性抗体及其制备方法和应用
CN105777906A (zh) * 2014-12-19 2016-07-20 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
CN107428832A (zh) * 2015-01-09 2017-12-01 新加坡科技研究局 抗pd‑l1抗体
CN106939047A (zh) * 2016-01-04 2017-07-11 钜川生物医药 一种pd-l1抗体及其制备方法
CN107488229A (zh) * 2016-06-13 2017-12-19 臧敬五 Pd‑l1抗体及其用途
WO2018057669A1 (en) * 2016-09-21 2018-03-29 Alexo Therapeutics Inc. Antibodies against signal-regulatory protein alpha and methods of use
CN106699891A (zh) * 2017-01-25 2017-05-24 北京天广实生物技术股份有限公司 一种抗pd‑l1 抗体、其药物组合物及其用途
CN107298713A (zh) * 2017-08-15 2017-10-27 联合益康（北京）生物科技有限公司 一种抗pd‑l1抗体及应用、制备方法、试剂盒和药物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RICHARD等: "An Effective Immuno-PET Imaging Method to Monitor CD8-Dependent Responses to Immunotherapy", 《CANCER RESEARCH》 *
斯卡登道夫等: "《皮肤恶性黑色瘤手册》", 31 October 2014, 天津科技翻译出版有限公司 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023000675A1 (zh) * 2021-07-23 2023-01-26 安徽安科生物工程（集团）股份有限公司 靶向pd-l1和4-1bb的双特异性抗体
CN116120461A (zh) * 2022-04-29 2023-05-16 德琪(杭州)生物有限公司 新型抗药抗体以及其用途
CN116120461B (zh) * 2022-04-29 2023-09-29 德琪(杭州)生物有限公司 新型抗药抗体以及其用途

Also Published As

Publication number Publication date
IL277893A (en) 2020-11-30
JP7360720B2 (ja) 2023-10-13
CN113087799A (zh) 2021-07-09
EP3778635A4 (en) 2022-01-26
CN110869390B (zh) 2021-05-11
CL2020002600A1 (es) 2021-01-29
JP2021530430A (ja) 2021-11-11
CO2020013833A2 (es) 2020-12-21
US11993655B2 (en) 2024-05-28
KR20200140882A (ko) 2020-12-16
ZA202006255B (en) 2022-03-30
PH12020551661A1 (en) 2021-06-07
JP2023179558A (ja) 2023-12-19
CN113121698A (zh) 2021-07-16
CN113087799B (zh) 2023-03-31
CA3095498A1 (en) 2019-10-17
IL297847B1 (en) 2023-10-01
IL297847B2 (en) 2024-02-01
IL297847A (en) 2023-01-01
EA202092420A1 (ru) 2021-01-28
US20210380698A1 (en) 2021-12-09
CN113121698B (zh) 2022-11-01
CN115991778A (zh) 2023-04-21
AU2018418224A1 (en) 2020-11-26
EP3778635A1 (en) 2021-02-17
MX2020010653A (es) 2020-10-28
BR112020020637A2 (pt) 2021-03-23
SG11202009791VA (en) 2020-11-27
WO2019196309A1 (zh) 2019-10-17

Similar Documents

Publication Publication Date Title
CN107151269B (zh) 一种pdl-1抗体、其药物组合物及其用途
AU2015295936B2 (en) Anti-CTLA4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
CN110869390A (zh) 抗pd-l1抗体及其用途
US9840561B2 (en) Human anti-human epidermal growth factor receptor antibody and encoding gene and application thereof
CN109762066A (zh) 4-1bb抗体及其制备方法和应用
KR102058381B1 (ko) 인간 ｌ１ｃａｍ에 대한 인간화 항체 및 그의 제조 방법
CA3022308A1 (en) Humanized anti-basigin antibodies and the use thereof
KR20170138551A (ko) Fab-dsFv 다량체 종에서 단량체 항체의 백분율을 증가시키는 방법
CA3111462A1 (en) Improved anti-flt3 antigen binding proteins
KR20220121808A (ko) 항-pd-l1/항-b7-h3 다중특이적 항체 및 이의 용도
KR20220167331A (ko) 항-flt3 항체 및 조성물
EP3623383A1 (en) Improved bispecific flt3xcd3 antigen binding proteins
EP4286520A1 (en) Antigen binding protein and use thereof
IL301566A (en) ZIP12 antibodies
US20210261677A1 (en) Anti-pd-l1 antibody and use thereof
CN111205371A (zh) 一种抗淋巴细胞激活基因3的抗体及应用
CN115521379B (zh) Pd-1抗体及其用途
CN115521378B (zh) Pd-l1抗体及其用途
CN114656562B (zh) 结合人和猴cd3的抗体及其应用
CN113004416B (zh) 靶向her2-cd137双特异性抗体的构建及其应用
WO2022141378A1 (zh) 一种抗pd-1的单域抗体
EA044684B1 (ru) Антитело против pd-l1 и его применение
CN117355540A (zh) 抗cd137抗体和使用方法
CN117396516A (zh) 抗cea抗体和使用方法
CN114539407A (zh) 一种全人源抗PD-1的单克隆抗体No.1-10及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20200623

Address after: 201203 Room 201, floor 2, building 4, No. 1118, Halley Road, free trade zone, Pudong New Area, Shanghai

Applicant after: SHANGHAI ORIGINCELL MEDICAL TECHNOLOGY Co.,Ltd.

Address before: 201203 Room 201, floor 2, building 4, No. 1118, Halley Road, free trade zone, Pudong New Area, Shanghai

Applicant before: SHANGHAI ORIGINCELL MEDICAL TECHNOLOGY Co.,Ltd.

Applicant before: Li Bohua

TA01 Transfer of patent application right
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40024438

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address

Address after: 201203 Shanghai Pudong New Area Free Trade Pilot Zone, Room 201, 2nd floor, Building 1118 Harley Road, Shanghai

Patentee after: Yuanqi Biotechnology (Shanghai) Co.,Ltd.

Address before: 201203 Room 201, 2nd floor, building 4, no.1118, Halley Road, Pudong New Area Free Trade Zone, Shanghai

Patentee before: SHANGHAI ORIGINCELL MEDICAL TECHNOLOGY Co.,Ltd.

CP03 Change of name, title or address